Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.
about
Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer ImmunotherapyB7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer.Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution.NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions with Diverse Ligands and Alterations in Splice Variant ExpressionGenetic discoveries and treatment advances in neuroblastoma.Dendritic cell-derived exosomes for cancer therapy.NKp30 isoforms in patients with chronic hepatitis C virus infection.The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.New B7 Family Checkpoints in Human Cancers.Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis.Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer.NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.Natural killer cell mediated immunosurveillance of pediatric neuroblastomaNatural Killer Cells: Angels and Devils for Immunotherapy.BPTF inhibits NK cell activity and the abundance of natural cytotoxicity receptor co-ligands.NKp30 and its ligands: emerging players in tumor immune evasion from natural killer cells.The B7 Family Member B7-H6: a New Bane of Tumor.The prognostic value of B7-H6 protein expression in human oral squamous cell carcinoma.Splice variants of human natural cytotoxicity receptors: novel innate immune checkpoints.Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastomaTNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancerNatural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy
P2860
Q26772347-4E24D4C7-B0B0-4D98-BC2B-D1950E6961A2Q36095328-962D94DD-1ACF-4499-99DA-F11667CD857EQ36821101-F4431849-A4D7-4D82-A969-714A1C326B8BQ37224577-89F5EB1A-F4A5-4340-928B-67B2A964DC8DQ37558627-7DC13844-B016-4929-93F3-4AC432F83CDCQ37616478-564474D5-56F5-4826-BC0B-F222ABA6C952Q37616484-C6FE705D-4059-4BDB-A860-1F80696C0119Q37727470-FD69B580-C62D-43F5-8DC1-5720E6912DA9Q38635551-743E251A-9120-4793-A42C-97845C5AFACAQ38795623-E0CEBBA6-F3B3-4EF7-9A53-2D642CF931A2Q38861721-25AB3FFE-E36D-430D-AE1A-239D1B150BE8Q39397418-C5299BE3-F903-4CFD-9316-0EDAA3C3BE23Q39416195-38379CCD-8A9E-4B9A-9135-44FC18512AEFQ40098295-3E53F629-212C-4818-B5B2-79CB2B7404D5Q41144481-98C52DB3-2121-42CB-B570-689127F7600DQ41472587-B81085D5-7B01-47B2-9112-9AE4ED08C7A9Q41578364-75DDBA42-E0CA-432D-95A4-CD9A0E8DF611Q41661175-B3908969-A513-41C5-A9B8-1C9947A14D00Q41979268-F13352C3-5E6E-468F-B551-4227FD77F99FQ43143910-D703EBA4-91B8-4460-B6ED-E91A93A0E6F6Q48098708-884D772D-E832-4406-A0B2-A291F961E872Q48239951-16EE4BE2-D746-4C66-A539-0F53FFE4D7D7Q49630355-FA1EA3A8-B8FF-421D-8F2C-C66180C44C19Q57824724-10478A42-969F-4942-906A-02EA52A75735Q58621104-27B012EC-1463-4811-8F9A-128AA929CF6DQ58764532-685FDED1-4426-4D2E-8AD2-7B4036ED880E
P2860
Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.
@en
type
label
Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.
@en
prefLabel
Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.
@en
P2093
P2860
P50
P1476
Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.
@en
P2093
Andrei Tchirkov
Benjamin Papoular
Brigitte Bressac
Christelle Piperoglou
David Enot
Françoise Farace
Frédéric Commo
Jessica Matta
Laurence Brugieres
Nicolas F Delahaye
P2860
P304
P356
10.1126/SCITRANSLMED.AAA2327
P407
P50
P577
2015-04-01T00:00:00Z